Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2024-07-31 , DOI: 10.1111/apt.18158
Brian G Feagan _{1,

2} , Katsuyoshi Matsuoka ₃ , Gerhard Rogler ₄ , David Laharie ₅ , Séverine Vermeire ₆ , Silvio Danese _{7,

8} , Edward V Loftus ₉ , Ian Beales _{10,

11} , Stefan Schreiber ₁₂ , Hyo Jong Kim ₁₃ , Margaux Faes ₁₄ , Angela de Haas ₁₅ , Tomasz Masior ₁₆ , Christine Rudolph ₁₅ , Laurent Peyrin-Biroulet _{17,

18,

19,

20,

21,

22}

Affiliation

Alimentiv Inc., London, Ontario, Canada.
Western University, London, Ontario, Canada.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan.
Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Gastroenterology Department, Hospital Center University de Bordeaux, Magellan Medico-Surgical Center, Haut-Lévêque Hospital, University of Bordeaux, INSERM, Bordeaux, France.
Department of Gastroenterology and Hepatology, UZ Leuven, Leuven, Belgium.
Department of Gastroenterology and Endoscopy, IRCCS Hospital San Raffaele, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Department of Gastroenterology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
University of East Anglia, Norwich, UK.
Department Internal Medicine I, Kiel University, University Hospital Schleswig-Holstein, Kiel, Germany.
Department of Gastroenterology, Center for Crohn's and Colitis, Kyung Hee University, South Korea.
Galapagos NV, Mechelen, Belgium.
Galapagos NV, Leiden, Netherlands.
Galapagos GmbH, Basel, Switzerland.
Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
INSERM, NGERE, University of Lorraine, Nancy, France.
INFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
FHU-CURE, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
Private Hospital Group Ambroise Paré - Hartmann, Paris IBD Center, Neuilly-sur-Seine, France.
Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada.

Filgotinib, an oral, once-daily, Janus kinase 1 preferential inhibitor, is an approved treatment for moderately to severely active ulcerative colitis.

中文翻译：